Skip to main content

Table 4 Summary of Pharmacokinetic Parameters of Metformin

From: Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin

Treatment

Day- 1 Metformin alone

Day 13 Metformin + RE

AUC

(0-tau)

(hr.ng/mL)

Cmax

(ng/mL)

tmax

(hr)

AUC

(0-tau)

(hr.ng/mL)

Cmax

(ng/mL)

tmax

(hr)

Metformin +

12,305

1967

2.0

13,955

2041

2.5

Placebo

(20)

(22)

(0.5–4.0)

(24)

(24)

(0.75–8.0)

Metformin +

13,895

2162

3.0

14,693

2166

2.5

RE 500 mg

(24)

(24)

(0.5–4.0)

(25)

(28)

(0.75–4.0)

Metformin +

11,319

1758

2.5

11,392

1695

2.0

RE 750 mg +

(33)

(26)

(0.5–4.0)

(37)

(34)

(0.5–4.1)

  1. RE Remogliflozin Etabonate
  2. Values are geometric mean (%CVb) for each parameter, except for tmax which are median (range)